New York Life Investment Management LLC Takes Position in Elanco Animal Health Incorporated $ELAN

New York Life Investment Management LLC acquired a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 41,903 shares of the company’s stock, valued at approximately $948,000.

Several other institutional investors have also modified their holdings of the business. Legacy Capital Group California Inc. lifted its holdings in shares of Elanco Animal Health by 3.1% during the 4th quarter. Legacy Capital Group California Inc. now owns 20,988 shares of the company’s stock valued at $475,000 after purchasing an additional 632 shares in the last quarter. AlphaQuest LLC lifted its holdings in shares of Elanco Animal Health by 13.7% during the 3rd quarter. AlphaQuest LLC now owns 5,953 shares of the company’s stock valued at $120,000 after purchasing an additional 718 shares in the last quarter. Jones Financial Companies Lllp lifted its holdings in shares of Elanco Animal Health by 15.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 6,065 shares of the company’s stock valued at $119,000 after purchasing an additional 798 shares in the last quarter. US Bancorp DE lifted its holdings in shares of Elanco Animal Health by 1.9% during the 3rd quarter. US Bancorp DE now owns 43,810 shares of the company’s stock valued at $882,000 after purchasing an additional 824 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. lifted its holdings in shares of Elanco Animal Health by 80.3% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after purchasing an additional 900 shares in the last quarter. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Down 0.8%

ELAN stock opened at $19.78 on Wednesday. The company has a current ratio of 2.16, a quick ratio of 1.12 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $9.88 billion, a PE ratio of -39.55, a PEG ratio of 2.14 and a beta of 1.69. Elanco Animal Health Incorporated has a 1-year low of $12.40 and a 1-year high of $27.72. The business’s 50 day simple moving average is $23.16 and its 200 day simple moving average is $23.31.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. The company had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.28 billion. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. Elanco Animal Health’s quarterly revenue was up 14.9% compared to the same quarter last year. During the same quarter last year, the company posted $0.37 EPS. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, research analysts anticipate that Elanco Animal Health Incorporated will post 1.11 EPS for the current year.

Insider Transactions at Elanco Animal Health

In related news, CEO Jeffrey N. Simmons purchased 4,971 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The shares were acquired at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the purchase, the chief executive officer owned 171,971 shares in the company, valued at approximately $3,454,897.39. This represents a 2.98% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Rajeev A. Modi purchased 4,911 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The stock was bought at an average price of $20.35 per share, for a total transaction of $99,938.85. Following the purchase, the insider owned 160,812 shares in the company, valued at $3,272,524.20. The trade was a 3.15% increase in their position. The SEC filing for this purchase provides additional information. 1.14% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a report on Saturday. UBS Group reiterated a “buy” rating on shares of Elanco Animal Health in a report on Tuesday, March 10th. Morgan Stanley lifted their target price on Elanco Animal Health from $22.00 to $24.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 25th. Citigroup lifted their target price on Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Finally, KeyCorp lifted their target price on Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $28.20.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.